3 Oct 2012 - United States - Employment and HR - How to Tell Which Employees Must Be Offered Coverage Under Health Care Reform - Thompson Coburn LLP - Employers with employees who work variable hours or seasonally should determine whether they...
BERLIN – Intermittent use of continuous glucose monitoring during pregnancy failed to improve glycemic control or cut the rate of neonatal macrosomia in a single-center, randomized study with 149 women with diabetes.
In 1983 a young Frances Ashcroft sat alone in her new laboratory at Oxford University's Department of Physiology, Anatomy, and Genetics, plagued by doubts. “I felt pretty useless as a scientist at the time, and I didn't think I was terribly good in the lab”, she recalls. But she was, she says, “quite good at connecting ideas”; one instance of which was to apply the newly minted patch-clamp technique for studying the activity of ion channels to pancreatic β-cells, with the expectation that something interesting might turn up. It did. A year later she published a seminal paper in Nature that established the ATP-sensitive potassium channel (KATP channel) as the crucial link between blood glucose concentration and insulin secretion, which propelled her to the forefront of efforts to understand how cells regulate themselves in health and disease, and in diabetes in particular. Now a Royal Society Research Professor in that same Oxford lab, the decades since Ashcroft's breakthrough discovery have brought awards by the bucket load, while her gift for explaining the intricacies of ion channels (and science in general) in a way that doesn't make people want to flee in panic has seen her attain a degree of celebrity quite rare for a scientist. When The Lancet spoke to her in early June she was in the throes of preparing for an appearance at the Hay Festival to talk about her new book, The Spark of Life: Electricity in the Human Body. (Her first popular science work, Life at the Extremes—the Science of Survival, made it onto the best-seller lists and was translated into 13 languages.)...
Christine Nolan climbed 17,500 feet to the base camp of Mount Everest in 2011. Her type I diabetes made the arduous climb an even greater challenge, but Nolan is determined not to let her condition define her life.
By AmyT on September 24, 2012 You all know about Diabetes Art Day today, right? It’s an ever-growing “web-based initiative for the Diabetes Online Community to ‘tell a story’ about life with diabetes though creative visual expression,” dreamed up and organized by one of our fave DOC’ers Lee Ann Thill.....
LCT announces positive DIABECELL Phase I/IIa trial September 2012 Results of the New Zealand Phase I/IIa clinical trial. Download PDF version DIABECELL clinical trial update September 2012 An update on DIABECELL's Phase I/IIa clinical trials in New Zealand and Argentina. Download PDF version
"We are pleased that Rick is joining Asante as we prepare to enter the U.S. market with the launch of the Pearl™ Insulin Pump," said David Thrower, Asante's president and chief executive officer. "Rick is an accomplished and recognized sales leader in the insulin pump category as well as a proven community leader, educator and speaker on diabetes topics. He has more than 20 years of progressive achievements, from hands-on sales representation to regional and area sales management."
The Minnesota Medical Foundation helps people everywhere lead healthier lives by advancing health-related research, education, and care at the University of Minnesota.......
The U’s new sensor
To improve upon the current technology, Koester is testing a material called graphene that would be placed under the skin. “It’s a two-dimensional piece of carbon that’s one atom thick,” he explains.
He also is working on attaching receptors to the graphene sensor so that it can detect glucose. The sensor then wirelessly sends the data to the device’s computer, which tells the insulin pump what to do.
The wireless graphene sensor is much smaller than the current commercial sensor—about the size of a grain of sea salt. Because of the small size and lack of wires, Koester says, it could be put in more inconspicuous places.
“It’s a new way of doing sensing,” he says. “You could get a better glucose reading.”
Gathering more accurate glucose data would help patients who are living with diabetes, Kudva says. “If we get a more reliable signal, then we can fine-tune the insulin better.”.............
A steady stream of new apps and devices that can be synced to ever-more sophisticated mobile phones is flowing into consumers’ hands, and this technology is revolutionizing the practice of self-tracking, in which individuals measure and collect personal data to improve their heath.
Self-trackers are using these tools to monitor sleep, food intake, exercise, blood sugar and other physiological states and behaviors. In some cases, they are using the data to identify what triggers or worsens flare-ups of chronic health disorders on their own, or with the help of an online community. In others, patients are even working together with physicians and scientists to conduct experiments, pooling their data for analysis that may shed light on the cause or best treatment for their disease....
The European Medicines Agency has updated its guidance on biosimilar medicines, with the aim of helping companies to avoid unnecessary repetition of clinical trials. .....As the changes of interpretation are made based on the existing legislation, it means there will not be a lengthy legislative process.
A company founded on decades of research regarding C-peptide and long-term complications of type 1 diabetes is in phase 2 trials of a once-weekly C-peptide replacement therapy and is raising fresh capital.
While it is still waiting on a decision from the FDA, Denmark's Novo Nordisk ($NVO) has gotten got Japanese approval for its long-acting insulin Tresiba, a drug that could possibly rival Sanofi's ($SNY) blockbuster Lantus.
One night in 1984, British scientist Frances Ashcroft was studying electricity in the body and discovered the protein that causes neonatal diabetes. She says she felt so "over the moon" that she couldn't sleep.
By the next morning, she says, she thought it was a mistake.
But luckily, that feeling was wrong, and Ashcroft's revelation led to a medical breakthrough decades later, which now enables people born with diabetes to take pills instead of injecting insulin.
"I don't think people realize the excitement of being a true discoverer," Ashcroft tells Fresh Air's Terry Gross. "There are no new places to discover on this Earth, but there are many, many new ideas to discover — new things to find out about the way the world works."...
HORW, Switzerland, Sept. 26, 2012 /PRNewswire/ — CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company’s PaQ(® )Insulin Delivery Device. The study was designed to evaluate the ability of people with type 2 diabetes to use PaQ in replacing their multiple daily insulin injections required to control their blood sugar. Study endpoints included glycemic control, patient satisfaction and safety.
The study comprised three two-week periods: baseline, transition to PaQ, and PaQ treatment period. Professor Thomas Pieber and his team at the University Hospital Graz, Austria enrolled and completed the study in six months. CeQur expects to share initial results early next year.
PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor. PaQ is simple to use, making it easy to train patients to start and stay on therapy.
“Our data suggest that the transduction of transcription factors using SeV vectors facilitates mPSCs differentiation into insulin producing cells and showed the possibility of regenerating B-cells by using transduced PSCs,” the researchers concluded.
The study was published in a recent issue of Cell Medicine...
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.